Stock Market Reviews

SNSE (Sensei Biotherapeutics, Inc.) News

Get the latest news, insights, and market updates on SNSE (Sensei Biotherapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
  BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeuti
  Apr 2, 2025 - $SNSE
• Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
  - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage
  Mar 28, 2025 - $SNSE
• Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
  – Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 re
  Mar 27, 2025 - $SNSE
• What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
  Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Feb 6, 2025 - $SNSE
• Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
  BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET. A webcast of Sensei’s presentation will be available in th
  Feb 4, 2025 - $SNSE
• Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
  - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sens
  Jan 8, 2025 - $SNSE
• Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
  BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery an
  Nov 27, 2024 - $SNSE